Back to top
more

Replimune Group (REPL)

(Delayed Data from NSDQ)

$9.00 USD

9.00
1,784,162

+0.48 (5.63%)

Updated Jun 28, 2024 04:00 PM ET

After-Market: $8.98 -0.02 (-0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

1 item in cart

View Cart/Checkout

Replimune Group, Inc. [REPL]

Reports for Purchase

Showing records 101 - 120 ( 195 total )

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 101

03/01/2021

Industry Report

Pages: 3

You Are Invited to Our Virtual 33rd Annual ROTH Conference on March 15-17, 2021

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 102

02/05/2021

Company Report

Pages: 4

FY3Q21 Financials Reported; Raising PT to $60

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 103

02/05/2021

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 104

02/05/2021

Company Report

Pages: 6

Fiscal Q3; Busy 2021 for Entire Pipeline

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 105

02/04/2021

Company Report

Pages: 6

Program Updates. Several Trial Read-Outs in 2021.

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 106

01/12/2021

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 107

01/11/2021

Company Report

Pages: 5

All Programs Are a GO for 2021!

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 108

01/06/2021

Company Report

Pages: 4

First Patient Dosed With RP3; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 109

12/16/2020

Industry Report

Pages: 5

BEST IDEAS LIST

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 110

12/03/2020

Industry Report

Pages: 4

BEST IDEAS LIST

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 111

11/10/2020

Daily Note

Pages: 16

SITC 2020 Abstract Preview for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 112

11/10/2020

Company Report

Pages: 5

SITC Posters Impress; FY2Q21 Financials Reported; Raising PT to $58

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 113

11/06/2020

Company Report

Pages: 6

Fiscal Q2; SITC Data Presentation Ahead

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 114

11/06/2020

Daily Note

Pages: 27

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 115

11/06/2020

Daily Note

Pages: 8

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 116

11/05/2020

Company Report

Pages: 7

2Q20 - Mission Continues Against Solid Tumors

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 117

11/02/2020

Industry Report

Pages: 4

BEST IDEAS LIST -BIL November Update

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 118

10/27/2020

Company Report

Pages: 7

Additional Considerations Ahead of SITC

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 119

10/27/2020

Industry Report

Pages: 5

"Consider Reading" Vol. 18: Overcoming Resistance to Anti-PD-1 Therapy with Oncolytic Viruses

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 120

10/27/2020

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party